Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PortugalBack to Portugal

Clinical trials in Coimbra – page 20

263 clinical trials in Coimbra, Portugal across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Coimbra at a glance
263
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

263 trials in Coimbra

Open in trial search

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Lupus nephritis

Not recruiting

Study on the Effectiveness and Safety of Iptacopan with Drug Combination for Adults with Active Lupus Nephritis Class III-IV, +/- V

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Adenocarcinoma of colon

Not recruiting

Study of Dostarlimab and Drug Combination for Patients with Untreated Resectable Colon Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Glaxosmithkline Research & Development Limited

Complications of transplanted kidney+1

Not recruiting

Study on ARGX-117 for Improving Kidney Function in Patients with Delayed Graft Function After Deceased Donor Transplant

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Graves' disease

Not recruiting

Study on the Effects of Satralizumab for Patients with Moderate-to-Severe Thyroid Eye Disease

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Leiomyosarcoma metastatic

Not recruiting

Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Filgrastim
  • Sponsor:Pharma Mar S.A.

Pulmonary arterial hypertension

Not recruiting

Study on Seralutinib for Treating Pulmonary Arterial Hypertension in Patients

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib
  • Sponsor:GB002 Inc.

Bladder cancer

Not recruiting

Study Comparing Enfortumab Vedotin and Pembrolizumab with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Multiple sclerosis+2

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab, Methylprednisolone, and Diphenhydramine Hydrochloride in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer+2

Not recruiting

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Lung disorder

Not recruiting

Study on Baricitinib for Hospitalized Patients with Severe or Critical COVID-19

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Oslo University Hospital HF

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Coimbra

What the registry says about research in the country

01 Ophthalmology & Vision

Innovative trials investigating treatments for polypoidal choroidal vasculopathy and thyroid eye disease, focusing on improving visual outcomes and reducing eye-related complications.

  • Retinal conditions
  • Orbital disorders
  • Visual acuity improvement

Advanced therapeutic approaches using intravitreal injections and targeted medications.

02 Dermatology

Groundbreaking research addressing various skin conditions including hidradenitis suppurativa, pyoderma gangrenosum, and neurodermatitis.

  • Inflammatory skin diseases
  • Chronic skin conditions
  • Autoimmune dermatological disorders

Novel therapeutic approaches targeting specific inflammatory pathways.

03 Cardiovascular Medicine

Comprehensive studies exploring treatments for cardiovascular disease and pulmonary arterial hypertension, with focus on preventing major adverse cardiac events.

  • Heart disease prevention
  • Vascular conditions
  • Lipid management

Innovative therapies targeting specific cardiovascular risk factors.

04 Neurology

Advanced research in ischemic stroke, epilepsy, and migraine treatments, exploring both acute interventions and preventive therapies.

  • Stroke management
  • Seizure disorders
  • Headache conditions

Cutting-edge therapeutic approaches for neurological disorders.

05 Oncology

Studies focusing on breast cancer, non-small cell lung cancer, and leiomyosarcoma, developing targeted therapies for various cancer types.

  • Metastatic disease
  • Combination therapies
  • Targeted treatments

Innovative approaches in cancer treatment and management.

Back to PortugalAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.